Bayer Co.Lab will enhance biotech partnerships in Mainland China, supporting local drug discovery and R&D. Government efforts and multinational investments are poised to boost the pharmaceutical sector’s growth.
..
Bayer Co.Lab will enhance biotech partnerships in Mainland China, supporting local drug discovery and R&D. Government efforts and multinational investments are poised to boost the pharmaceutical sector’s growth.
Key takeaways
Bayer’s new Shanghai incubator will foster biotech innovation and local drug discovery partnerships in China.
Multinational drugmakers like AstraZeneca and Novartis are increasing R&D investments in Mainland China’s growing market.
China’s government is driving biotech innovation with incentives, boosting global partnerships and domestic drug development.
Bayer Co.Lab will facilitate local partnerships in Mainland China and enable pharmaceutical drug discovery by local players.
On September 27 2024, Bayer inaugurated its first life science co-creation platform called Bayer Co.Lab in the Shanghai Innovation Park in Zhangjiang Science City. Bayer Co.Lab is…